anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Limited data are available on the effects of duloxetine in patients with end-stage renal disease (ESRD). After a single 60 mg dose of duloxetine, C and AUC values were approximately 100% greater in patients with end-stage renal disease receiving chronic intermittent hemodialysis than in subjects with normal renal function. The elimination half-life, however, was similar in both groups. The AUCs of the major circulating metabolites, 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate, largely excreted in urine, were approximately 7- to 9-fold higher and would be expected to increase further with multiple dosing. Population PK analyses suggest that mild to moderate degrees of renal dysfunction (estimated CrCl 30-80 mL/min) have no significant effect on duloxetine apparent clearance . max[see Dosage and Administration ( ) and Warnings and Precautions ( )] 2.35.13
Participants will consume 4 identical meals, as in the other groups, except that the meal window will be restricted to 6.5 hours instead of 12 hours (meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (\<3 lux) throughout the 16-hour wake episode.
The 2010 Dietary Guidelines for Americans emphasizes consumption of 4.5 cups of fruits and vegetables daily. However, average fruit and vegetable intake of US adults is only 2.6 cups. This low consumption of fruits and vegetables may further result in the limited availability of fat soluble, health-promoting, phytochemicals such as carotenoids from these foods. Dietary carotenoids have beneficial biological properties including antioxidant and anti-inflammatory effects and scientific research supports the protective effects of carotenoids against many degenerative diseases, including cardiovascular diseases, age-related macular degeneration, and some types of cancer. Therefore, either low intake or inefficient bioavailability of carotenoids from fruits and vegetables may reduce their potential effectiveness as disease preventative compounds. The bioavailability of carotenoids from a meal can be affected by several factors, including food matrix, type of food processing or cooking, interactions with other dietary compounds during digestion and absorption, gut status which may affect digestion and absorption processes, and nutritional status. Co-consumption of carotenoid rich foods with dietary lipids may be one of the most effective stimulators of carotenoid absorption among factors that influence their bioaccessibility and bioavailability. Eggs are known to be a highly bioavailable source of carotenoids, presumably due to the presence of lipid and phospholipid in egg yolk. The highly bioavailable nature of carotenoids from eggs suggest that egg derived factors may be leveraged to improve bioavailability of other carotenoids found in co-consumed fruits and vegetables. While promising, very limited data exist on the impact of a co-consumed food source of lipid, such as eggs, to enhance carotenoid absorption. This study is designed to assess the beneficial effects of egg consumption on carotenoids absorption from a complex meal, beyond those found in egg.
FIELD: medicine, cardiology, pharmacy. SUBSTANCE: method involves assay of platelet guanylate cyclase activity stimulated with protoporphyrin IX. Monotherapy with nebivolol is prescribed if its activity is below 250 pmole/ /min/mg and nebivolol is combined with hydrochlorothiazide as an other antihypertension agent if enzyme activity is above 250 pmole/min/mg. Method provides differentiating effect on vasodilating function of endothelium tissue. EFFECT: decreased time for hypotensive effect attainment. 1 tbl, 2 ex
A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
The safety and effectiveness of a single dose and a 3-day regimen of fosaprepitant have been established in pediatric patients 6 months to 17 years for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC and MEC.

Use of fosaprepitant in this age group is supported by evidence from adequate and well-controlled studies of fosaprepitant for injection in adults, with additional safety, efficacy and pharmacokinetic data in pediatric patients 6 months to 17 years. Efficacy and safety were also supported by data from an adequate and well-controlled study of a 3-day oral aprepitant regimen in pediatric patients 6 months to 17 years. See the full prescribing information for aprepitant capsules for complete clinical information regarding studies performed with oral aprepitant. Adverse reactions were similar to those reported in adult patients. [See Dosage and Administration (2.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3)]. 

The safety and effectiveness of fosaprepitant for injection for the prevention of nausea and vomiting associated with HEC or MEC have not been established in patients less than 6 months of age.  
  
Juvenile Animal Toxicity Data    
In juvenile dogs treated with fosaprepitant, changes in reproductive organs were observed. In juvenile rats treated with aprepitant, slight changes in sexual maturation were observed without an effect on reproduction. No effects on neurobehavior, sensory and motor function, or learning and memory were observed in rats.   
  
In a toxicity study in juvenile dogs treated with fosaprepitant from postnatal day 14 (equivalent to a newborn human) to day 42 (approximately equivalent to a 2 year old human), decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and edema of vaginal tissues were seen in females from 4 mg/kg/day. A study was also conducted in young rats to evaluate the effects of aprepitant on growth and on neurobehavioral and sexual development. Rats were treated at oral doses up to the maximum feasible dose of 1000 mg/kg twice daily (providing exposure in male and female rats lower than the exposure at the recommended pediatric human dose) from the early postnatal period (Postnatal Day 10 (equivalent to a newborn human) through Postnatal Day 58 (approximately equivalent to a 15 year old human)). Slight changes in the onset of sexual maturation were observed in female and male rats; however, there were no effects on mating, fertility, embryonic-fetal survival, or histomorphology of the reproductive organs. There were no effects in neurobehavioral tests of sensory function, motor function, and learning and memory.

Additional pediatric use information is approved for Merck Sharp & Dohme LLC’s EMEND (fosaprepitant) for injection. However, due to Merck Sharp & Dohme LLC’s marketing exclusivity rights, this drug product is not labeled with that information.
In recent years, as a functional potential pseudocereal, chia seed (Salvia hispanica L.) has been of great interest for its comprehensive nutritional profile and attractive qualities after ingestion. It is reported that a reasonable dietary supplementation of chia seed (CS) contributes to the prevention and treatment of acute and chronic diseases (inflammation, diabetes, hypertension, obesity, kidney stone, etc.). CS contains a variety of bioactive macromolecular substances, such as oil, protein and gum, which manifest distinguished health-promoting activities in both in vivo and in vitro research studies. This article provides a comprehensive compendium on the functional importance of CS, in the context of biological activities and mechanism of actions of CS. Specifically, CS and its components alleviate inflammation and regulate glucose and fatty acid metabolism by regulating key influencing factors in the adenosine 5'-monophosphate-activated protein kinase (AMPK), mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), peroxisome-activated receptor gamma (PPAR-γ) and transforming growth factor-beta (TGF-β) pathways and the insulin receptor substrate (IRS)-mediated insulin signaling pathway. In the meantime, predictions of metabolic pathways of CS peptides based on the known tracks of newly researched active peptides were proposed, with the aim of emphasizing the enormous research space of CS peptides compared to other functional active peptides.
Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
The subject invention provides an agent and a method for atopy prophylaxis. Supplying gamma-linolenic acid, dihomo-gamma-linolenic acid, the physiologically compatible salts, esters, amides, phospholipids, glycolipids thereof, and Prostaglandin E1 (PGE1), PGE1 derivatives, PGE1 analogs to babies can prevent a subsequent occurrence of manifest atopy forms. The agents according to the invention are preferably contained in a baby food and/or should be supplied to the baby together therewith.          In a further preferred embodiment the agent contains a thymus hormone, or thymus hormones provided in combination with the agent. Further provided for is the use of Prostaglandin E1, its derivatives and analogs and the physiologically compatible esters, amides, phospholipids and glycolipids thereof in a pharmacologically effective dosage form for the topical or inhalative treatment of acute manifest atopy in the dermal and mucosal areas. The substance used according to the invention are preferably used in combination with gamma-linolenic acid, 15-hydroxydihomo-gamma-linolenic acid and dihomo-gamma-linolenic acid, the physiologically compatible salts, esters, amides, phospholipids and glycolipids thereof.
Physical therapy treatment of patients with lymphoedema includes treatment based on the principles of 'Complete Decongestive Therapy' (CDT). CDT consists of following components; skin care, manual lymphatic drainage, bandaging and exercises. Regarding what type of treatment of treatments is most effective, the scientific evidence is sparse. Studies have focused on the time-consuming manual lymphatic drainage, but the scientific evidence is not consistent.

A randomized, single-blind, equivalence trial. A total of 160 breast cancer patients with lymphoedema will be recruited from 3 hospitals and randomised into one of two treatment groups: A: Complete Decongestive TherapyA (incl. manual drainage) or B: Complete Decongestive TherapyB (except manual lymphatic drainage
Patients receive carboplatin IV and paclitaxel IV once weekly and undergo radiation therapy QD (Monday-Friday) beginning on day 1 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up and undergo collection of blood samples throughout the trial.
BACKGROUND: Proteinuria is a prevalent symptom of pediatric nephrology, while kidney biopsy remains the gold standard for kidney tissue analysis, and it is currently controversial. We report the rare case that the mutation in the AMN gene was considered to cause chronically isolated proteinuria and also suggest that renal biopsy should be chosen with caution in children with chronic isolated non-nephrotic levels of proteinuria and that genetic testing may be feasible for the early precise diagnosis.
CASE PRESENTATION: A 35-month-old boy presented with excessive urine foaming for more than half a month; his proteinuria was considered non-nephrotic range and urine protein electrophoresis was suggestive of mixed proteinuria; other than that, the investigations are non-specific. Given the child's chronic isolated proteinuria and good renal function, we chose to refine the genetic test rather than a renal biopsy; a compound heterozygous variant was found in the AMN gene of this child which was caused by a point mutation in the father, and a partial chromosomal deletion in the mother.
CONCLUSIONS: Cubilin(encoded by CUBN), amnionless(encoded by AMN), and megalin form a multiligand receptor complex; CUBN or AMN gene variants have been implicated as a hereditary cause of megaloblastic anemia, proteinuria, and neurological impairment. In the past few decades, chronic isolated proteinuria caused by CUBN gene variants is benign, non-progressive, and has normal renal function. However, the child is the first reported case of isolated proteinuria of AMN gene mutation, indicating that the earlier diagnostic genetic sequencing in an otherwise well, not nephrotic proteinuria child may be a convenient, cost-effective, and harmless option, challenging the traditional paradigm.
PURPOSE: To evaluate functional and structural assessments as endpoints for clinical trials for USH2A-related retinal degeneration.
METHODS: People with biallelic disease-causing variants in USH2A, visual acuity ≥ 20/80, and visual field ≥ 10° diameter were enrolled in a 4-year, natural history study. Participants underwent static perimetry, microperimetry, visual acuity, fullfield stimulus testing (FST), and optical coherence tomography annually. Rates of change estimated from mixed-effects linear models and percentages of eyes with changes exceeding the coefficient of repeatability (CoR) or thresholds conforming with U.S. Food and Drug Administration (FDA) guidelines were evaluated.
RESULTS: Rates of change were generally more sensitive to change than proportions of eyes exceeding a threshold such as the CoR. Baseline ellipsoid zone area ≥ 3 mm2 was necessary to detect change. Mean sensitivity and volumetric hill of vision measures on static perimetry had similar properties and were the most sensitive to changes of the continuous measures. The highest 4-year proportions of eyes exceeding the CoR were from FST testing (47%) and microperimetry (32%). Specification of loci as functional transition points (FTPs) resulted in 45% (static perimetry) and 46% (microperimetry) at 4 years, meeting FDA guidelines for progression.
CONCLUSIONS: Rate of change of mean sensitivity on static perimetry was a sensitive perimetric continuous measure. Percentages of within-eye change were largest with FST testing and microperimetry. FTPs appear to be particularly sensitive to change. These results affect clinical trial design for USH2A-related retinal degeneration.
TRANSLATIONAL RELEVANCE: Analyses of natural history data from the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) study can inform eligibility criteria and endpoints for clinical trials.
PROBLEM TO BE SOLVED: To enable enhancement of effect of anticancer agent by adding a tea catechin and/or a theaflavin to an anticancer agent. SOLUTION: An anticancer agent, especially an antimetabolite is mixed with a tea catechin and/or a theaflavin and administered. A tea catechin consisting essentially of epigallocatechin is especially preferable as the tea catechin and the amount of the tea catechin added is 5-20mg/kg. The theaflavin consists essentially of theaflavin digallate and the amount added is 5-10mg/kg. The anticancer agent in an amount of 1-20mg/kg is used. The effect of the anticancer agent is enhanced without adverse effects by the administration of the combination of the anticancer agent and/or the theaflavin.
The present invention relates to a food additive made of manyflower solomonseal rhizome, which is used as medicine and food, and a production technique of health care products thereof. After the original selection steps such as picking, elutriating, scraping, cutting, wetting, slicing, drying, etc. The manyflower solomonseal rhizome is braised in a vacuum condition for 2 to 4 hours at 100 to 120 DEG C; then the food additive made of manyflower solomonseal rhizome is prepared after the steps such as drying, pulverizing, sieving, etc. The health care medicine prepared from the food additive made of manyflower solomonseal rhizome, which is used as a major ingredient, and other traditional Chinese medicines has the auxiliary functions of lowering blood pressure, blood fat and blood sugar, preventing arterial sclerosis and coronary heart disease, etc. and can be made into a plurality of forms such as medicinal granules, capsules, etc.; thus, people can conveniently use.
This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
OBJECTIVES: I. Determine the response rate and toxicity profile of concurrent and consolidative chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) therapy compared to consolidative rituximab therapy in patients with chronic lymphocytic leukemia treated with fludarabine. II. Assess the complete response (CR) rate in patients receiving concurrent therapy with rituximab and fludarabine. III. Assess the frequency of conversion of a partial response (PR) to a CR or stable disease to either PR or CR in patients receiving consolidative therapy with rituximab. IV. Follow the effects of rituximab and fludarabine on the immunologic markers CD4, CD8, IgG, IgA, and IgM. V. Assess the progression-free and overall survival of these patients.

OUTLINE: This is a randomized study. Patients are stratified according to stage (I and II vs III and IV). Patients are assigned to 1 of 2 treatment arms. Arm I consists of fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction, and arm II consists of fludarabine induction. Arm I: Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks. Arm II (Fludarabine Induction): Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A maximum of 100 patients will be accrued for this study within 12 months.
Compositions and methods for forming, in an aqueous environment, a nanoaggregate of calcium fluoride and amorphous calcium phosphate-containing compound, such as amorphous calcium phosphate fluoride or amorphous calcium carbonate phosphate fluoride are described. The nanoaggregate (or nanocomposite) can release calcium, phosphate, and fluoride, and ultimately convert to the tooth mineral, fluorapatite. One method for forming such a nanoaggregate involves applying a non-aqueous (e.g., varnish-based) composition (e.g., a suspension), containing solid particles of water soluble salts of calcium, phosphate, and fluoride, to the aqueous environment of the mouth. This results in rapid solubilization of the salts, precipitation of the nanoaggregate, and tooth remineralization. Tooth fluoridation and remineralization may also be carried out by applying to the tooth a non-aqueous carrier containing the nanoaggregate. Whitening agents can also be added to these compositions and methods.
The invention discloses an antibacterial peptide with antifungal effect, a preparation method and application thereof, and relates to the technical field of biology. The amino acid sequence of the antibacterial peptideIs Ac-WKKWFR-NH 2 The antibacterial peptide has antibacterial activity on candida albicans, and the minimum inhibitory concentration on the candida albicans is 50 mug/mL. It can destroy the integrity of Candida albicans cell wall, and cause the increase of cell membrane permeability in a short time. The antibacterial peptide treated Candida albicans has abnormal and irregular cell structure, causes cytoplasmic protoplasm disorder, and has multiple vacuoles inside the cell. The antimicrobial peptides can bind to Candida albicans genomic DNA, inducing an increase in intracellular ROS. The prepared antibacterial peptide can be widely applied to the fields of medicine raw materials, food, fruit and vegetable preservation and preservation, plant fungal disease control, feed additives and the like as an antibacterial agent.
PROBLEM TO BE SOLVED: To provide a coating formulation free from adhesion of the coating formulation, coating material, core material or the like to the coating pan in an excess amount in a coating operation, capable of easily obtaining a smooth surface and enabling an easy coating operation. Therefore provides a method easily controlling a process and enabling automation of the equipment because the process has no reduction of coating layer forming rate in the coating operation without wasting the solution for forming a coating layer. SOLUTION: This method coats the core material with a coating layer by using a coating layer forming solution including 1 pts.wt. of a suspension base per 1 pts.wt. of a maltitol composition including the maltitol >=90 wt.% andmaltotriitol and maltotetraitol <=3 wt.%. based on the solid content.
The initial dose of HLX51 is 0.3mg/kg, and 5 dose levels are designed: 0.3 mg/kg, 1 mg/kg , 2.5mg/kg, 5mg/kg, and 10mg/kg (Q3W). Patients with good tolerability and well controlled disease will receive the treatment until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.